- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Commends 340B Drug Discount Accountability Act
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act (HR 6240), introduced by Representative Chris Collins, R-New York, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration (HRSA).
The legislation will ensure that HRSA receives additional resources needed to properly oversee and administer the program, according to COA. The user fees would go toward program oversight, audits, and monitoring of the program.
Grantees and non-hospital covered entities would be exempt. The bill would also give HRSA “direct-hire authority” for new employees to implement and conduct the oversight.
Read more about the legislation and the full press release here.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
